Experts Discuss Common AEs With EGFR TKIs

Video

Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP discuss common adverse effects with EGFR TKIs.

Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP discuss common adverse effects (AEs) with EGFR TKIs.

Zosia Piotrowska, MD, is a clinical researcher and lung cancer medical oncologist, Massachusetts General Hospital Cancer Center. Christine Lovly, MD, is an associate professor of medicine, Division of Hematology-Oncology, an Ingram associate professor of Cancer Research, co-leader, the Translational Research and Interventional Oncology Program, Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center. Amanda Cass, PharmD, BCPS, is a clinical pharmacist, the Thoracic Oncology Clinic, Vanderbilt University Medical Center.

Lovly, Piotrowska, and Cass, explain that the inhibition of EGFR wild-type, which is commonly expressed in the skin, mucous membranes, and the gut, can lead to many of the skin toxicities associated with EGFR TKIs.

Moreover, the 3 experts discuss the adverse effects specifically associated with the use of osimertinib (Tagrisso). Osimertinib can lead to nail bed changes, rash, and sun sensitivity. Additionally, it is important to take up-front preventative measures to attempt to mitigate these skin toxicities.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS